Bottneuro AG

Bottneuro, a startup from the University of Basel on the Novartis campus, provides a fully personalized neurostimulation therapy based on each patient's MRI data. Our device is registered with SWISSMEDIC, MHRA, and EUDAMED as a Custom Made Device, allowing neurologists and psychiatrists in Switzerland, the UK, and the EU to prescribe it for Alzheimer's, stroke, epilepsy, depression, and psychiatric disorders. We've completed the first human study, and we're now treating first patients in Switzerland.